Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group
Joachim von Pawel, Reinhard von Roemeling, Ulrich Gatzemeier et al. · Journal of Clinical Oncology · 2000
PURPOSE: A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles. RESULTS: A total of 446 patients with NSCLC (17% with stage IIIB disease and pleural effusions; 83% with stage IV disease) were entered onto the study. Karnofsky performance status (KPS) was >/= 60 for all patients (for 10%, KPS = 60; for 90%, KPS = 70 to 100). Sixty patients (14%) had clinically stable brain metastases. The median survival was significantly longer (34.6 v 27. 7 weeks; P =.0078) and the response rate was significantly greater (27.5% v 13.7%; P <.001) for patients who received tirapazamine plus cisplatin (n = 218) than for those who received cisplatin alone (n = 219). The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting. There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine. CONCLUSION: The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.
Cited by 285 works. doi:10.1200/jco.2000.18.6.1351
Authors
- Joachim von Pawel
- Reinhard von Roemeling
- Ulrich Gatzemeier
- Michael Joseph Boyer
- Lars Ove Elisson
- Peter I. CLARK
- Denis Talbot
- Augustin A. Rey
- Thomas Wayne Butler
- Vera Hirsh
- Ian Olver
- Bengt Bergman
- Gary Edward Richardson
- David J. Dunlop
- Anthony G. Arcenas
- Robert Allen Vescio
- Jean Viallet
- Joseph Treat
References
- Cancer statistics, 1998
- The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
- The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
- Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
- Management strategies for recurrent non-small cell lung cancer.
- A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.
- SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
- SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
- Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer
- Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.